😀

😀

😀

NVIDIA and Microsoft are likely to deliver the most impressive results this quarter.
NVIDIA continues to ride the AI boom, and demand for their GPUs hasn't cooled down.
Microsoft is integrating AI into its products at a crazy pace, plus strong cloud growth via Azure keeps pushing their revenue up.
Meanwhile, cautious about Apple and Meta — consumer spending is softer, and ad markets aren't fully recovered globally.

😀

Summary and translation: Roche cooperates with Zealand Pharma to develop a weight loss drug.
On Wednesday, Roche and the Danish biotechnology company Zealand Pharma (ZLDPF.US) announced a licensing agreement to jointly develop and market Zealand's experimental weight loss drug, Petrelintide.
Petrelintide is an analog of amylin, designed to mimic the actions of the amylin hormone naturally produced by the body. This hormone is released along with insulin during meals, slowing gastric emptying, enhancing satiety, and possessing other metabolic regulatory functions. In contrast, Novo-Nordisk's Wegovy primarily acts on GLP-1 receptors, which play a key role in regulating blood sugar and metabolic functions.
In recent years, pharmaceutical companies have begun to focus on amylin analogs as alternatives to GLP-1 to reduce common gastric discomfort. Novo-Nordisk A/S's new generation weight-loss medication will...